Alethia Young

Bulls have emerged in defense of Celgene Corporation (NASDAQ: CELG) as the sell-off continues after unfavorable news from the U.S. Food and Drug Administration. Both William Blair and Credit Suisse advised investors to keep buying. The Rating Credit Suisse analyst Alethia Young reiterated an...

The Street may be too optimistic in its outlook for Gilead Sciences, Inc. (NASDAQ: GILD) — and this isn't a bullish indicator, according to Credit Suisse. The Analyst Credit Suisse's Alethia Young downgraded Gilead's stock rating from Outperform to Neutral with a price target...

Shares of PTC Therapeutics, Inc. (NASDAQ: PTCT) gained more than 13 percent Friday after the FDA found that the company's experimental drug to treat Duchenne muscular dystrophy may work. The FDA's Advisory Committee meeting ruled that the body of evidence for the company's ataluren...

PTC Therapeutics, Inc. (NASDAQ: PTCT) is already experiencing some major volatility Tuesday ahead of its upcoming AdCom meeting for Duchenne muscular dystrophy drug candidate Translarna on Thursday. The stock took a 22-percent dive Tuesday morning ahead of the meeting as investors have started to...

Credit Suisse analyst Alethia Young reiterated an Outperform rating on Sarepta Therapeutics Inc (NASDAQ: SRPT) with a $64 price target, following the announcement of a new CEO and ahead of several other catalysts. Sarepta announced Wednesday that Doug Ingram has been appointed CEO. He will...

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) announced Wednesday the appointment of Paul Clancy as its chief financial officer, effective July 31, though he is expected to join the company on July 10. Previously, Clancy served as the CFO of biotech firm Biogen Inc (NASDAQ: BIIB) for a decade...

The American Society of Clinical Oncology’s annual meeting ended Tuesday. The event was filled with updates on clinical trials and research. Credit Suisse analyst Alethia Young released her key findings from Monday’s session regarding Puma Biotechnology Inc (NASDAQ: PBYI), Incyte...

Shares of Puma Biotechnology Inc (NASDAQ: PBYI) hit a new 52-week high of $80.00 Thursday morning after the company confirmed that the U.S. Food and Drug Administration's Oncologic Drugs Advisory Committee voted 12–4 to recommend approval of PB272 (neratinib) for the treatment of early stage...

Is M&A in the cards for Gilead Sciences, Inc. (NASDAQ: GILD)? Credit Suisse analysts Alethia Young and Eliana Merle think so. In a note reviewing the company's first-quarter results, the analysts said they think the company is mobilizing for a deal. Investors Focus On Potential Deal Credit...

2017 could see a slew of biotech M&As, especially from Gilead Sciences, Inc. (NASDAQ: GILD) which acknowledged M&A is a priority for the company this year. Speculations are rife about potential Gilead interest in Incyte Corporation (NASDAQ: INCY), and Credit Suisse says a Gilead-Incyte...

Following a stay granted to allow Regeneron Pharmaceuticals Inc (NASDAQ: REGN)'s PCSK9 franchise Praluent to stay in the market, Credit Suisse said the development is a mild positive for the company. The firm said the company's shares would trade up 2–4 percent based on the headline news,...

Shares of Sarepta Therapeutics Inc (NASDAQ: SRPT) soared as high as $63.73 following a controversial decision by the U.S. Food and Drug Administration to approve the company's treatment of Duchenne muscular dystrophy in September 2016. Since the FDA's announcement, the stock has lost more than half...

According to public pricing database PriceRx, Biogen Inc (NASDAQ: BIIB)'s Spinraza could cost $125,000 per dose. “We had estimated a gross annual price of $450k,” Credit Suisse’s Alethia Young said in a report. She maintains a Neutral rating on the company, with a price target of...

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) announced on November 9 that its 10Q filing would be delayed due to the ongoing investigation into the company’s sales practices. Credit Suisse’s Alethia Young maintains an Outperform rating on the company with a price target of $165. Delayed...

Credit Suisse initiated coverage of AC Immune Ltd (NASDAQ: ACIU) with an Outperform rating and an $18 price target. Alzheimer's Pure Play Analyst Alethia Young noted that the company's lead product crenezumab is in a late-stage trial in partnership with Roche Holding Ltd. (ADR) (OTC: RHHBY)....